You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 18, 2024

Claims for Patent: 9,592,208

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 9,592,208

Title:	Formulations comprising 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol
Abstract:	A solid pharmaceutical composition suitable for oral administration, comprising: (a) a S1P receptor modulator; (b) a filler, and (c) a cyclodextrin.
Inventor(s):	Rane; Supriya (Parsippany, NJ)
Assignee:	Novartis AG (Basel, CH)
Application Number:	14/009,241
Patent Claims:	1. A solid pharmaceutical composition suitable for oral administration, comprising a) a first compound selected from 2-amino-2-[2-(4-octylpheny)hethyl]propane-1,3-diol, a pharmaceutically acceptable salt thereof, and a phosphate derivative thereof, b) a filler, and c) a stabilizer against the inducement of degradation products, wherein the stabilizer comprises a cyclodextrin or a derivative thereof, wherein the cyclodextrin or derivative thereof is natural cyclodextrin, a branched cyclodextrin, an alkyl-cyclodextrin or a hydroxyalkyl-cyclodextrin, and wherein the pharmaceutical composition is in unit dosage form, each unit comprising less than 0.5 mg of the first compound. 2. The composition according to claim 1, wherein the filler comprises a sugar alcohol. 3. The composition according to claim 1, further comprising a binder. 4. The composition according to claim 1, further comprising a lubricant. 5. The composition according to claim 1, wherein the stabilizer comprises hydroxypropyl-beta-cyclodextrin. 6. The composition according to claim 1, wherein the first compound is 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol or a pharmaceutically acceptable salt thereof. 7. The composition according to claim 2, wherein the sugar alcohol is mannitol. 8. The composition according to claim 3, wherein the binder is hydroxypropyl cellulose. 9. The composition according to claim 1, wherein the cyclodextrin or derivative thereof is selected from the group consisting of .alpha.-cyclodextrin; .beta.-cyclodextrin, .gamma.-cyclodextrin; hydroxypropyl-cyclodextrin, sulfobutylether .beta.-cyclodextrin, dodecakis-2,6,O-methyl-.alpha.-cyclodextrin, tetradecakis-2,6,O-methyl-.beta.-cyclodextrin, hexadecakis-2,6,O -methyl-.gamma.-cyclodextrin, tetradecakis-2,6,O-ethyl-.beta.-cyclodextrin, .alpha.-cyclodextrin partially etherized with 2-hydroxypropyl, .beta.-cyclodextrin partially etherized with 2-hydroxypropyl, branched .alpha.-cyclodextrin, and branched .beta.-cyclodextrin where glucose or maltose has been bound via .alpha.-1,6 glucoside bond. 10. The composition according to claim 4, wherein the lubricant is magnesium stearate. 11. A method of reducing the frequency of clinical exacerbations, delaying the progression of symptoms or disorders associated with multiple sclerosis or delaying the accumulation of physical disability induced by multiple sclerosis in a patient in need thereof, comprising administering a therapeutically effective amount of the solid pharmaceutical composition according to claim 1.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.